Who is sponsoring NCT05905887?

NCT05905887 is sponsored by Asan Medical Center.

What drugs are being tested in NCT05905887?

Interventions in NCT05905887: Rivoceranib Mesylate, Paclitaxel.

What condition does NCT05905887 study?

NCT05905887 studies Gastrointestinal Stromal Tumors.

Is NCT05905887 still recruiting?

NCT05905887 is currently recruiting now. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT05905887

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Recruiting now Phase 2 Last updated 7 April 2026

What this trial tests

Phase 2 trial testing Rivoceranib Mesylate, Paclitaxel in Gastrointestinal Stromal Tumors in 48 participants. Currently enrolling.

Timeline

6 September 2023

Primary endpoint
31 August 2027

31 December 2027

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	6 September 2023
Primary completion	31 August 2027
Estimated completion	31 December 2027
Sites	1 location across South Korea

Drugs / interventions tested

Rivoceranib Mesylate, Paclitaxel — full drug profile →

Conditions studied

Gastrointestinal Stromal Tumors — all drugs for Gastrointestinal Stromal Tumors →

Sponsor

Asan Medical Center

Who can join

20 and older, any sex, with Gastrointestinal Stromal Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape.
Belančić A, Prejac J, Golčić M, Adžić G, et al · · 2026 · PMID 42075805 · DOI 10.3390/ph19040548

Verify or expand the search:

Other recruiting trials for Gastrointestinal Stromal Tumors

Currently open trials in the same condition.

NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
NCT06326346 — GIST Oral Paclitaxel(Liporaxel) · Phase 2 · recruiting
NCT06087263 — Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation · Phase 2 · active not recruiting
NCT05366816 — ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST · Phase 2 · recruiting
NCT05661643 — The Efficacy and Safety of Temozolomide in SDH-deficient GIST · Phase 2 · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05905887 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05905887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing